Dooyoung Jung1, Kwang-Min Lee, Won-Hyoung Kim, Joo-Young Lee, Tae-Yong Kim, Seock-Ah Im, Kyung-Hun Lee, David Spiegel, Bong-Jin Hahm. 1. From the Department of Human Factors Engineering (Jung), Ulsan National Institute of Science and Technology, Ulsan, Korea; Department of Psychiatry and Behavioral Sciences (Jung, K-M Lee, Hahm), Seoul National University College of Medicine, Seoul, Korea; Department of Neuropsychiatry (K-M Lee, Hahm), Seoul National University Hospital, Seoul, Korea; Department of Psychiatry (W-H Kim), Inha University Hospital, Incheon, Korea; Department of Health Management (J-Y Lee), Armed Forces Medical Command, Seongnam, Korea; Department of Internal Medicine (T-Y Kim, Im, K-H Lee), Seoul National University Hospital, Seoul, Korea; Department of Internal Medicine (Im), Seoul National University College of Medicine, Seoul, Korea; Cancer Research Institute (T-Y Kim, Im, K-H Lee), Seoul National University, Seoul, Korea; Department of Psychiatry and Behavioral Sciences (Spiegel), Stanford University, Stanford, California.
Abstract
OBJECTIVE: Risk factors for chemotherapy-induced nausea and vomiting (CINV) include older age, female sex, alcohol consumption, and a history of motion sickness. Although gastrointestinal symptoms are found to be related with sleep and mood in other conditions, little is known about their effects on CINV. METHODS: This prospective observational study recruited patients with early-stage breast cancer who had recovered from surgery before receiving a first cycle of anthracycline and cyclophosphamide-based chemotherapy. Candidate factors associated with CINV were assessed before chemotherapy by using the following: the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, the Epworth Sleepiness Scale, and the Hospital Anxiety and Depression Scale. Chemotherapy-induced nausea (CIN) and chemotherapy-induced vomiting (CIV) were defined according to a numeric rating scale (0-10) as follows: ≥3, nausea; ≥1, vomiting. RESULTS: Between February 2012 and May 2014, data were collected from 198 patients. Chemotherapy-induced nausea occurred in 35.4% of patients, and CIV occurred in 31.3%. Chemotherapy-induced nausea was significantly associated with poor sleep quality (odds ratio [OR], 2.48; 95% confidence interval [CI], 1.13-5.46; p = 0.024) and pretreatment nausea (OR, 4.81; 95% CI, 1.84-12.62; p = 0.001). Likewise, CIV was significantly associated with poor sleep quality (OR, 2.64; 95% CI, 1.21-5.78; p = 0.015) and pretreatment nausea (OR, 3.07; 95% CI, 1.23-7.66; p = 0.016). CONCLUSIONS: Poor sleep quality increases risk of CINV in patients with breast cancer. Sleep problems should be assessed and considered in the management of CINV.
OBJECTIVE: Risk factors for chemotherapy-induced nausea and vomiting (CINV) include older age, female sex, alcohol consumption, and a history of motion sickness. Although gastrointestinal symptoms are found to be related with sleep and mood in other conditions, little is known about their effects on CINV. METHODS: This prospective observational study recruited patients with early-stage breast cancer who had recovered from surgery before receiving a first cycle of anthracycline and cyclophosphamide-based chemotherapy. Candidate factors associated with CINV were assessed before chemotherapy by using the following: the Pittsburgh Sleep Quality Index, the Insomnia Severity Index, the Epworth Sleepiness Scale, and the Hospital Anxiety and Depression Scale. Chemotherapy-induced nausea (CIN) and chemotherapy-induced vomiting (CIV) were defined according to a numeric rating scale (0-10) as follows: ≥3, nausea; ≥1, vomiting. RESULTS: Between February 2012 and May 2014, data were collected from 198 patients. Chemotherapy-induced nausea occurred in 35.4% of patients, and CIV occurred in 31.3%. Chemotherapy-induced nausea was significantly associated with poor sleep quality (odds ratio [OR], 2.48; 95% confidence interval [CI], 1.13-5.46; p = 0.024) and pretreatment nausea (OR, 4.81; 95% CI, 1.84-12.62; p = 0.001). Likewise, CIV was significantly associated with poor sleep quality (OR, 2.64; 95% CI, 1.21-5.78; p = 0.015) and pretreatment nausea (OR, 3.07; 95% CI, 1.23-7.66; p = 0.016). CONCLUSIONS: Poor sleep quality increases risk of CINV in patients with breast cancer. Sleep problems should be assessed and considered in the management of CINV.
Authors: Komal Singh; Steven M Paul; Kord M Kober; Yvette P Conley; Fay Wright; Jon D Levine; Paule V Joseph; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-11-02 Impact factor: 3.612
Authors: Susan Grayson; Susan Sereika; Caroline Harpel; Emilia Diego; Jennifer G Steiman; Priscilla F McAuliffe; Susan Wesmiller Journal: Support Care Cancer Date: 2021-07-10 Impact factor: 3.603